GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
Clinical-stageLyophilised vialAlso known as:Mod GRF 1-29 · Modified GRF (1-29) · CJC-1295 DAC · CJC-1295 with DAC · CJC-1295 without DAC · DAC:GRF
DAC form 5.8–8.1 days (human; Teichman et al. 2006) · no-DAC form: no peer-reviewed figure found
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
2 mg, 5 mg, 10 mg
What it is
The compound. Origin, research and regulatory reality.
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29), developed by ConjuChem Biotechnologies in the mid-2000s. It is a tetrasubstituted form of GHRH(1-29) (Jetté et al., 2005). The name covers two chemically distinct forms.
A Phase II study in healthy adults (Teichman et al., 2006, J Clin Endocrinol Metab) reported that subcutaneous CJC-1295 with DAC produced sustained, dose-dependent increases in GH and IGF-I over several weeks. ConjuChem's Phase II programme in HIV-associated visceral adiposity (NCT00267527) was terminated in 2006 and development did not resume; the trials reviewed here did not evaluate body-composition or performance outcomes.
Neither form is approved as a medicine anywhere; both are sold research-use-only, and GHRH analogues are named on the WADA Prohibited List under S2, prohibited at all times for tested athletes. The DAC form carries a maleimidopropionyl linker that binds serum albumin, giving a reported half-life of 5.8–8.1 days (Teichman et al., 2006). The no-DAC form (Mod GRF 1-29) lacks the linker and is cleared far faster; we found no peer-reviewed half-life figure for it.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
It is sold research-use-only, for laboratory research rather than human use. Neither the DAC nor the no-DAC form is an approved medicine anywhere, and RUO labelling does not authorise personal administration.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC form binds blood albumin and persisted for 5.8–8.1 days in the Phase II trial, giving sustained GH/IGF-1 elevation. The no-DAC form (Mod GRF 1-29) lacks that linker and is cleared far faster; we found no peer-reviewed half-life figure for it.
What should a CoA show for CJC-1295?
Confirm which form was tested: the DAC form carries an extra lysine-linker residue, so the two forms differ in mass and the LC-MS result must match the form named on the label. Then check HPLC purity, lot number and an independent lab name.